Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
NCT07103278Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-116 in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve during dosing interval and Maximum concentration of drug in plasma. Started Jan 2026; status: completed.
02
Drugs
AD-116
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07103278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103278.